session

82 - Oral Communication
COVID-19
Feb. 26, 2021, 1:45 p.m. - 3:15 p.m., Rome

Abstract

2
Derivation and Validation of a Predictive Score for Disease Worsening in Patients with COVID-19
G. Gerotziafas1, T. Sergentanis2, G. Voiriot1, L. Lassel1, C. Papageorgiou1, A. Elabbadi1, M. Turpin1, P. Vandreden3, 1, L. Papageorgiou1, T. Psaltopoulou2, E. Terpos2, M. A. Dimopoulos2, A. Parrot1, J. Cadranel1, G. Pialloux1, I. Elalamy1, M. Fartoukh1, Presenter: G. Gerotziafas1 (1Paris, 2Athens, 3Gennevilliers)

Background and Objective
The prospective observational study conducted at the COVID-19 center of Tenon University Hospital in Paris aimed to develop a risk assessment model (RAM) for early identification of COVID-19 patients at risk for worsening disease.
Methods
Patients with confirmed COVID-19 (n=420) were devided in derivation (n=300) and validation (n=120) cohorts and stratified to those hospitalized at the conventional ward (C-group) and those with worsening disease (W-group). The study end point was disease worsening. All patients were routinely evaluated with full blood count, prothrombin time (PT), fibrinogen, D-Dimers, antithrombin and protein C activity. Data from the first hospitalization day at the conventional ward or the ICU were analyzed.
Results
Obesity, hypertention, diabetes and male gender, increased fibrinogen and D-Dimers, thrombocytopenia, AT-deficiency, lymphopenia and compensated DIC-ISTH score ≥5 were significant risk factors for worsening disease. The COMPASS-COVID-19 risk assessment model (RAM) derived from multivariate analysis includes: obesity, gender, compensated DIC, hemoglobin, and lymphocyte count. The score has a very good discriminating capacity to stratify patients at high and low risk for worsening disease, with AUC value at 0.77, sensitivity 81% and specificity 60%. Application of the COMPASS-COVID-19 score at the validation cohort showed 96% sensitivity and 45% specificity.
Conclusion
The COMPASS-COVID-19 score could serve as an accurate clinical decision tool for an easy identification of 80% COVID-19 patients at risk for disease worsening leading to prompt application of compassionate treatments including antithrombotic agents.
Our site saves small pieces of text information (cookies) on your device in order to deliver better content and for statistical purposes. You can disable the usage of cookies by changing the settings of your browser. By browsing our website without changing the browser settings you grant us permission to store that information on your device.